Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANXGet Rating) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 78,100 shares, a growth of 125.1% from the April 30th total of 34,700 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 152,900 shares, the short-interest ratio is presently 0.5 days.

GANX has been the subject of a number of research analyst reports. B. Riley decreased their price objective on shares of Gain Therapeutics from $16.00 to $11.00 in a report on Monday, May 23rd. HC Wainwright began coverage on shares of Gain Therapeutics in a research note on Tuesday, March 29th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Gain Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday.

A number of large investors have recently modified their holdings of GANX. Millennium Management LLC grew its stake in Gain Therapeutics by 66.2% during the second quarter. Millennium Management LLC now owns 23,878 shares of the company’s stock valued at $239,000 after acquiring an additional 9,511 shares in the last quarter. Veritable L.P. bought a new stake in Gain Therapeutics during the third quarter valued at approximately $187,000. UBS Group AG lifted its position in Gain Therapeutics by 64.4% during the third quarter. UBS Group AG now owns 6,740 shares of the company’s stock valued at $51,000 after purchasing an additional 2,640 shares during the last quarter. Telemetry Investments L.L.C. lifted its position in Gain Therapeutics by 217.7% during the third quarter. Telemetry Investments L.L.C. now owns 96,232 shares of the company’s stock valued at $716,000 after purchasing an additional 65,939 shares during the last quarter. Finally, CM Management LLC lifted its position in Gain Therapeutics by 39.9% during the fourth quarter. CM Management LLC now owns 90,000 shares of the company’s stock valued at $489,000 after purchasing an additional 25,673 shares during the last quarter. 8.89% of the stock is owned by institutional investors.

Shares of GANX traded up $0.17 during trading hours on Friday, hitting $2.89. The company’s stock had a trading volume of 91,749 shares, compared to its average volume of 118,818. The company has a market cap of $34.34 million, a price-to-earnings ratio of -2.37 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.63 and a quick ratio of 14.78. The business has a 50 day simple moving average of $3.56 and a two-hundred day simple moving average of $4.65. Gain Therapeutics has a 52-week low of $2.33 and a 52-week high of $10.90.

Gain Therapeutics (NASDAQ:GANXGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. The company had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.06 million. Gain Therapeutics had a negative net margin of 7,212.75% and a negative return on equity of 40.43%. Research analysts predict that Gain Therapeutics will post -1.33 earnings per share for the current year.

Gain Therapeutics Company Profile (Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

Featured Stories

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.